Symptomatic brain metastases in melanoma

IF 3.5 3区医学 Q1 DERMATOLOGY

Experimental Dermatology Pub Date : 2024-04-12 DOI:10.1111/exd.15075

Andrea Knox, Tim Wang, Mark Shackleton, Malaka Ameratunga

引用次数: 0

Abstract

Although clinical outcomes in metastatic melanoma have improved in recent years, the morbidity and mortality of symptomatic brain metastases remain challenging. Response rates and survival outcomes of patients with symptomatic melanoma brain metastases (MBM) are significantly inferior to patients with asymptomatic disease. This review focusses upon the specific challenges associated with the management of symptomatic MBM, discussing current treatment paradigms, obstacles to improving clinical outcomes and directions for future research.

Abstract Image

查看原文本刊更多论文

黑色素瘤的症状性脑转移

尽管近年来转移性黑色素瘤的临床治疗效果有所改善，但无症状脑转移瘤的发病率和死亡率仍是一项挑战。无症状黑色素瘤脑转移（MBM）患者的应答率和生存率明显低于无症状患者。本综述重点探讨与无症状脑转移瘤治疗相关的具体挑战，讨论当前的治疗范例、改善临床疗效的障碍以及未来的研究方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Experimental Dermatology 医学-皮肤病学

CiteScore

6.70

自引率

5.60%

发文量

201

审稿时长

2 months

期刊介绍： Experimental Dermatology provides a vehicle for the rapid publication of innovative and definitive reports, letters to the editor and review articles covering all aspects of experimental dermatology. Preference is given to papers of immediate importance to other investigators, either by virtue of their new methodology, experimental data or new ideas. The essential criteria for publication are clarity, experimental soundness and novelty. Letters to the editor related to published reports may also be accepted, provided that they are short and scientifically relevant to the reports mentioned, in order to provide a continuing forum for discussion. Review articles represent a state-of-the-art overview and are invited by the editors.